logo
Bell Potter Reaffirms Their Buy Rating on Cedar Woods Properties Limited (CWP)

Bell Potter Reaffirms Their Buy Rating on Cedar Woods Properties Limited (CWP)

In a report released today, Connor Eldridge from Bell Potter maintained a Buy rating on Cedar Woods Properties Limited (CWP – Research Report), with a price target of A$7.30.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
In a report released yesterday, Shaw and Partners also maintained a Buy rating on the stock with a A$7.00 price target.
The company has a one-year high of A$6.00 and a one-year low of A$4.30. Currently, Cedar Woods Properties Limited has an average volume of 55.81K.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies
Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Business Insider

time6 hours ago

  • Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Sarepta price target lowered to $30 from $84 at JPMorgan
Sarepta price target lowered to $30 from $84 at JPMorgan

Business Insider

time7 hours ago

  • Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

Business Insider

time7 hours ago

  • Business Insider

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store